Calcitonin salmon recombinant - Generic Drug Details

What are the generic sources for calcitonin salmon recombinant and what is the scope of patent protection?

Calcitonin salmon recombinant is the generic ingredient in one branded drug marketed by Upsher Smith Labs and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for calcitonin salmon recombinant

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	15
Clinical Trials:	22
DailyMed Link:	calcitonin salmon recombinant at DailyMed

Recent Clinical Trials for calcitonin salmon recombinant

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Missouri-Columbia	Phase 4
University of Maryland	Phase 4
University of Maryland, Baltimore	Phase 4

See all calcitonin salmon recombinant clinical trials

Paragraph IV (Patent) Challenges for CALCITONIN SALMON RECOMBINANT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FORTICAL	Nasal Spray	calcitonin salmon recombinant	200 IU/spray	021406	1	2006-03-29

US Patents and Regulatory Information for calcitonin salmon recombinant

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upsher Smith Labs	FORTICAL	calcitonin salmon recombinant	SPRAY, METERED;NASAL	021406-001	Aug 12, 2005		DISCN	No	No

Expired US Patents for calcitonin salmon recombinant

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upsher Smith Labs	FORTICAL	calcitonin salmon recombinant	SPRAY, METERED;NASAL	021406-001	Aug 12, 2005
Upsher Smith Labs	FORTICAL	calcitonin salmon recombinant	SPRAY, METERED;NASAL	021406-001	Aug 12, 2005
Upsher Smith Labs	FORTICAL	calcitonin salmon recombinant	SPRAY, METERED;NASAL	021406-001	Aug 12, 2005

Calcitonin Salmon Recombinant Market Dynamics, Patent Status, and Financial Trajectory

Last updated: September 3, 2026

Calcitonin salmon recombinant is a mature peptide medicine with limited commercial momentum. In the United States, the relevant products are calcitonin-salmon injection and nasal spray, historically marketed as Miacalcin and Fortical. The products have lost meaningful patent exclusivity, face low-cost generic competition, and operate in therapeutic areas where newer treatments have displaced calcitonin.

The commercial outlook is declining or stable at a low base rather than growth-oriented. The remaining market is concentrated in short-term treatment of hypercalcemia, selected Paget's disease use, and limited osteoporosis treatment where alternatives are unsuitable. Calcitonin is no longer a core therapy for osteoporosis because of weak fracture-prevention performance and regulatory concern over a possible malignancy signal associated with long-term use. [1][2]

What is calcitonin salmon recombinant?

Calcitonin salmon is a 32-amino-acid peptide that reduces serum calcium and inhibits bone resorption. It is more potent and longer-acting than human calcitonin. Commercial formulations have been supplied primarily as:

Formulation	Historical brand	Main route	Principal uses
Injectable calcitonin salmon	Miacalcin	Intramuscular or subcutaneous	Hypercalcemia, Paget's disease, postmenopausal osteoporosis
Nasal spray calcitonin salmon	Miacalcin, Fortical	Intranasal	Postmenopausal osteoporosis
Generic nasal spray	Multiple ANDA products	Intranasal	Primarily osteoporosis
Generic injection	Multiple suppliers over time	Injectable	Hypercalcemia and Paget's disease

The term "recombinant" requires technical qualification. U.S. commercial labels generally identify the active ingredient as calcitonin salmon, often described as synthetic salmon calcitonin rather than as a separately regulated recombinant biologic. The products are regulated as conventional drugs, not as biosimilars under the Public Health Service Act. [3][4]

What FDA indications apply to calcitonin salmon?

The FDA-approved indications are narrow and differ by formulation.

Injectable calcitonin salmon

Injection has historically been approved for:

• Emergency treatment of hypercalcemia.
• Paget's disease of bone.
• Selected postmenopausal osteoporosis use.

The hypercalcemia indication is commercially important because it can support hospital and specialty use. It is usually episodic rather than chronic, limiting recurring prescription volume.

Nasal calcitonin salmon

Nasal spray was approved for postmenopausal osteoporosis in women more than five years after menopause when alternative treatments are not suitable. Its use is constrained by:

• Limited efficacy relative to bisphosphonates and anabolic agents.
• Availability of oral and injectable alternatives.
• Long-term safety concerns.
• Declining physician use in osteoporosis guidelines.

The European Medicines Agency concluded that the benefits of calcitonin did not outweigh the risks for several chronic indications and recommended withdrawal of nasal calcitonin for osteoporosis in the European Union. [5]

When does calcitonin salmon lose exclusivity?

Calcitonin salmon has already lost its principal U.S. exclusivity.

The relevant commercial products were developed decades ago. Miacalcin and Fortical do not have meaningful remaining composition-of-matter exclusivity. Any remaining protection has been limited to formulation, device, manufacturing, or method-of-use claims, and those barriers have not prevented generic entry.

Exclusivity category	Current position
New chemical entity exclusivity	Expired
Core composition patent protection	Expired
Nasal spray formulation protection	Largely expired or commercially ineffective
Injectable product protection	Expired
Pediatric exclusivity	Not a current commercial barrier
Orphan exclusivity	Not a principal barrier
Biosimilar exclusivity	Not applicable
Generic entry	Established or historically available

The market therefore operates primarily under abbreviated new drug application, or ANDA, competition rather than branded patent exclusivity.

What is the Orange Book status of calcitonin salmon?

The FDA Orange Book has historically listed branded calcitonin-salmon products, including Miacalcin injection and Fortical nasal spray, alongside related generic products and therapeutic-equivalence information. Orange Book relevance is strongest for:

• Product-specific patents listed by the reference sponsor.
• Paragraph IV certification disputes.
• Therapeutic-equivalence ratings for generic nasal sprays and injections.
• Determining whether a product remains actively marketed.

The commercial importance of any remaining Orange Book listing is low compared with products that have active blocking patents. A generic applicant can generally challenge expired or nonblocking claims without confronting a durable market-exclusion period. [3]

Product availability has changed over time because sponsors have discontinued or transferred products. An Orange Book listing does not prove that a branded product remains commercially available. FDA discontinued-product records and current labeling must be reviewed together with Orange Book data.

Which companies have marketed calcitonin salmon?

The historical competitive field includes:

Company	Product or role	Commercial position
Novartis	Miacalcin	Original major branded supplier
Upsher-Smith Laboratories	Fortical	Branded nasal spray supplier
Apotex and other generic manufacturers	Calcitonin-salmon nasal spray or injection	Generic competition
Hospital and specialty suppliers	Injectable products	Institutional and episodic demand

The market has not developed into a concentrated biologics franchise. Manufacturing is comparatively accessible for an established peptide, although sterile injectable production, nasal-device performance, analytical characterization, and supply reliability remain operational barriers.

What patent litigation and Paragraph IV challenges affected calcitonin salmon?

The primary patent disputes occurred during the transition from branded nasal spray to generic competition. The disputes focused on nasal delivery, formulation, and product-specific patents rather than on a durable new-molecule patent estate.

The relevant legal pattern was typical for an aged product:

1. The reference product sponsor listed formulation or delivery patents.
2. Generic applicants filed ANDAs with Paragraph IV certifications.
3. Litigation risk centered on claim scope and patent validity.
4. Expiration or settlement removed the principal barrier to launch.
5. Multiple suppliers reduced the branded product's pricing power.

No current, market-defining Paragraph IV dispute is broadly recognized as a major barrier to U.S. generic access. The present commercial risk is therefore price erosion and product discontinuation rather than a new wave of patent litigation.

What formulations are protected by calcitonin salmon patents?

Historical patent activity has focused on four technical areas:

Nasal spray formulations

Nasal calcitonin products require stable peptide formulations that support mucosal absorption. Patent claims have addressed:

• Preservatives.
• Stabilizers.
• Absorption enhancers.
• Buffer systems.
• Peptide concentration.
• Spray-device delivery characteristics.

These claims can delay generic entry if they remain enforceable and listed. Their value declines sharply when alternative formulations can support an ANDA or when the claims expire.

Injectable formulations

Injection patents have generally provided less commercial protection because the underlying dosage form is conventional and the products are old. Sterile manufacturing and peptide quality controls are more important than patent exclusion.

Device and delivery systems

Nasal devices can create practical development barriers even where patent protection is weak. A generic sponsor must demonstrate pharmaceutical equivalence and acceptable delivery performance. These requirements may reduce the number of suppliers but do not preserve branded pricing once multiple products are approved.

Method-of-use claims

Method-of-use patents have had limited long-term effect. Chronic osteoporosis use has declined because the treatment's clinical position weakened, reducing the value of additional indication claims.

How strong is the calcitonin salmon patent estate?

The patent estate is weak by specialty-pharmaceutical standards.

Patent-strength factor	Assessment
Core molecule	Very weak; old peptide
Composition claims	Expired
Nasal formulation claims	Historically relevant, now limited
Device claims	Potentially relevant but narrow
Manufacturing claims	Operational value greater than exclusion value
Method-of-use claims	Reduced value because of limited clinical use
Biosimilar barriers	None
Generic substitution risk	High

The most defensible remaining know-how is likely to involve manufacturing consistency, peptide impurity control, sterile filling, device compatibility, and supply-chain execution. Those assets can support commercial reliability but do not create the pricing power associated with an active composition patent.

What generic entry risks exist for calcitonin salmon?

Generic entry risk is high for both nasal and injectable products.

The principal risks to branded revenue are:

• Therapeutic-equivalent substitution.
• Multiple ANDA suppliers.
• Pharmacy and hospital purchasing pressure.
• Declining use in osteoporosis.
• Low switching costs for established formulations.
• Product discontinuation by the reference sponsor.
• Reduced physician willingness to prescribe chronic calcitonin.

Nasal spray products can retain modest differentiation through device performance, tolerability, packaging, and supply consistency. These factors are insufficient to support premium pricing when FDA-approved generics are available.

Injectable products may have somewhat better commercial defensibility because hospital procurement values dependable supply and sterile manufacturing. That advantage is operational rather than patent-based.

How does calcitonin salmon compare with competing osteoporosis drugs?

Calcitonin has been displaced by therapies with stronger fracture-reduction evidence and more favorable reimbursement profiles.

Therapy	Relative position versus calcitonin
Alendronate and other bisphosphonates	Lower cost, stronger osteoporosis evidence
Denosumab	More effective chronic antiresorptive option for many patients
Teriparatide and abaloparatide	Anabolic options for high-risk patients
Romosozumab	Potent specialty option for selected high-risk patients
Calcitonin salmon	Narrow fallback role and weak commercial growth profile

Calcitonin retains a role in acute hypercalcemia and selected Paget's disease cases. Its chronic osteoporosis role is largely residual. The FDA added labeling language regarding a possible increased cancer risk after reviewing clinical-trial data, which further weakened demand in long-term osteoporosis. [1]

What is the financial trajectory for calcitonin salmon?

The financial trajectory is characterized by peak-to-trough erosion rather than expansion.

Revenue drivers

Remaining revenue is supported by:

• Hospital demand for injectable treatment of hypercalcemia.
• Specialty use in Paget's disease.
• Patients unable to use first-line osteoporosis drugs.
• Established generic prescriptions.
• Periodic supply shortages that can temporarily improve pricing.

Revenue pressures

Revenue is reduced by:

• Generic substitution.
• Loss of branded exclusivity.
• Low clinical priority in osteoporosis.
• Safety-related label changes.
• Reimbursement restrictions.
• Low prescription growth.
• Sponsor discontinuations and portfolio rationalization.

Public company filings generally do not provide a separate current revenue line for calcitonin salmon. Miacalcin and related products have been immaterial relative to the portfolios of large pharmaceutical companies. Fortical sales have also represented a small product franchise relative to the broader specialty and generic markets. Product-level revenue estimates from commercial datasets are therefore more useful than corporate annual reports, but they are not consistently disclosed in public filings.

The likely financial profile is:

Period	Financial trajectory
1980s-1990s	Branded growth across osteoporosis and metabolic bone disease
2000s	Mature branded product with nasal-spray competition
2010s	Generic entry, safety concerns, and declining osteoporosis use
2020s	Low-growth or declining mature market, with episodic injectable demand

What manufacturing and intellectual-property barriers remain?

Manufacturing barriers are more important than patent barriers.

Peptide manufacturing

Calcitonin salmon production requires:

• Reproducible peptide synthesis or biological production.
• Tight control of truncated sequences and related impurities.
• Validated analytical methods.
• Stability control.
• Reliable sterile or nasal-product manufacturing.

Injectable production

Injectables require sterile manufacturing capacity, validated aseptic processes, container-closure integrity, and dependable hospital distribution. These requirements can limit the number of active suppliers.

Nasal products

Nasal sprays require consistent emitted dose, spray-pattern control, device compatibility, microbial control, and stability after opening. These factors increase development complexity but do not provide lasting exclusivity once generic equivalence has been established.

What is the outlook for licensing and business development?

Large pharmaceutical companies have limited incentives to license calcitonin salmon as a standalone asset. The product has:

• Low growth potential.
• Weak patent protection.
• Significant generic exposure.
• Limited use in major chronic indications.
• No biosimilar or platform opportunity.
• Modest differentiation among suppliers.

Licensing interest is more plausible for:

• Regional distribution rights.
• Hospital injectable supply.
• Contract manufacturing.
• Portfolio acquisitions by specialty or generic companies.
• Reformulation with a new delivery system.

A transaction would likely be valued on current cash flow, manufacturing reliability, and supply contracts rather than on future patent-protected growth.

What generic launch scenarios are most likely?

The most likely commercial scenarios are:

Base case

Generic nasal and injectable products remain available, with low prices and modest residual demand. Branded products either remain niche offerings or are discontinued.

Downside case

Manufacturers exit because of low margins, leaving intermittent shortages and unstable supply. Volume falls but prices temporarily rise during shortages.

Specialty-stability case

Injectable demand remains relatively stable in hospitals and endocrine settings, while nasal osteoporosis demand continues to decline.

Upside case

A new delivery system or formulation improves adherence or creates a differentiated indication. This would require clinical and regulatory investment that is difficult to justify without meaningful exclusivity.

What is the geographic coverage of calcitonin salmon?

The United States remains a regulated generic market with established historical products. European use has been more restricted following regulatory action against chronic osteoporosis use. Other markets may retain injectable or nasal products for hypercalcemia, Paget's disease, or osteoporosis, but commercial potential varies with local reimbursement and generic competition.

Geographic opportunity is highest where:

• Injectable supply is limited.
• Calcitonin remains in treatment guidelines.
• Generic competition is fragmented.
• Hospital procurement rewards reliable supply.

It is weakest in markets where bisphosphonates, denosumab, and anabolic therapies have displaced calcitonin.

Key takeaways

• Calcitonin salmon is a mature peptide drug with little remaining patent-based exclusivity.
• The term "recombinant" does not create a separate U.S. biologic or biosimilar market for the established products.
• Miacalcin and Fortical are the principal historical branded references.
• Generic competition is the primary commercial threat.
• Nasal osteoporosis demand is structurally weak because of limited efficacy, safety concerns, and superior alternatives.
• Injectable demand has greater resilience because of acute hypercalcemia and specialty use.
• Current value lies in manufacturing, sterile supply, device execution, and distribution rather than in composition patents.
• Licensing potential is limited and would likely center on regional rights, supply, or reformulation.
• The financial trajectory is declining to low-level stability, with episodic volatility from shortages and supplier exits.

FAQs

Is calcitonin salmon still FDA approved?

Yes. FDA-approved calcitonin-salmon products and labeling have existed for injection and nasal spray, although individual brands and generic products may be discontinued or intermittently marketed. [3][4]

Is calcitonin salmon a biologic drug?

The established U.S. products are regulated as conventional drugs rather than as biosimilars. The active peptide may be manufactured synthetically or through a recombinant process, but the regulatory pathway depends on the approved product and application.

Can calcitonin salmon treat osteoporosis effectively?

It has an approved historical role in postmenopausal osteoporosis, but its clinical and commercial position is weak compared with bisphosphonates, denosumab, and anabolic therapies. Long-term use is generally limited to cases in which alternatives are unsuitable. [1][2]

Does calcitonin salmon have orphan-drug potential?

The established indications do not create a meaningful orphan exclusivity position. Acute hypercalcemia and Paget's disease are specialized uses, but specialization alone does not provide orphan exclusivity.

What is the strongest remaining competitive advantage for calcitonin salmon?

Reliable injectable supply is the strongest practical advantage. For nasal products, device performance and formulation consistency may differentiate suppliers, but neither factor replaces expired composition patents.

References

1. U.S. Food and Drug Administration. (2014). Miacalcin calcitonin salmon injection and nasal spray prescribing information. FDA.

2. U.S. Food and Drug Administration. (2013). Calcitonin salmon: Drug safety communication regarding possible increased risk of cancer. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drug database. FDA.

5. European Medicines Agency. (2012). European Medicines Agency recommends limiting long-term use of calcitonin medicines. EMA.